Monoclonal Antibodies

Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline

1 week ago talkbio0Tagged Acquisition, Anti-BTN3A Agonistic Monoclonal Antibody ICT01, BTN3A, butyrophilin superfamily, ImCheck Therapeutics, Immunotherapy, Ipsen, Leukemia, Myelocytic, Acute, Monoclonal Antibodies, Oncology Pipeline

Ipsen; ImCheck Therapeutics; acquisition; €350 million; €1 billion deal; immunotherapy; oncology pipeline; butyrophilin superfamily; ICT01; acute myeloid leukemia; monoclonal antibody; BTN3A

Allogene Reports Patient Death Linked to ALLO-647 Conditioning Antibody in CAR-T Trial

3 months ago talkbio0Tagged Adenovirus Infections, Allogene, ALPHA3 trial, Anti-CD52 Monoclonal Antibody ALLO-647, CAR-T, Liver Failure, Lymphodepletion Therapy, Monoclonal Antibodies, Patient Death

Allogene; ALLO-647; CAR-T; patient death; monoclonal antibody; lymphodepletion; large B-cell lymphoma; ALPHA3 trial; liver failure; adenovirus infection

ACIP Backs Merck’s Enflonsia for RSV Prevention in Infants

4 months ago talkbio0Tagged ACIP, Children Program, Enflonsia, Immunization, Infant, Merck, Monoclonal Antibodies, Respiratory syncytial virus, RSV, Vaccines

ACIP; Merck; Enflonsia; RSV; monoclonal antibody; infants; immunization; Vaccines for Children Program

Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines

4 months ago talkbio0Tagged Clinical Data, COVID19 (disease), immune compromise, Invivyd, long-acting protection, Monoclonal Antibodies, Pemgarda, vaccine alternatives

Invivyd; Pemgarda; VYD2311; monoclonal antibody; COVID-19; vaccine alternatives; immune compromise; long-acting protection; phase 1/2 clinical data

Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition

5 months ago talkbio0Tagged Approved, AstraZeneca, competition, Enflonsia, Infant, Market, Merck, Monoclonal Antibodies, Respiratory syncytial virus, sanofi, United States Food and Drug Administration

Merck; FDA approval; RSV; monoclonal antibody; infants; Enflonsia; competitive market; Sanofi; AstraZeneca

Galderma’s Nemluvio Secures Dual EU Approvals for Atopic Dermatitis and Prurigo Nodularis

9 months ago talkbio0Tagged Commission approval, Dermatitis, Atopic, European (ethnic group), Galderma, IL-31 receptor alpha, Monoclonal Antibodies, Nemluvio, nemolizumab, nodularis, Prurigo

Nemluvio, nemolizumab, Galderma, European Commission approval, atopic dermatitis, prurigo nodularis, IL-31 receptor alpha, monoclonal antibody

Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol

10 months ago talkbio0Tagged ANGPTL4, Cardiovascular Diseases, cholesterol, MAR001, Marea Therapeutics, Monoclonal Antibodies, Phase 2 Clinical Trials, Remnant

Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

10 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement